Pompe disease in infants: improving the prognosis by newborn screening and early treatment.
Yin-Hsiu Chien, Ni-Chung Lee, Beth L Thurberg...
https://pubmed.ncbi.nlm.nih.gov/19948615/Actively Recruiting
Led by University of California, San Francisco · Updated on 2026-03-17
10
Participants Needed
1
Research Sites
52 weeks
Total Duration
Researchers are evaluating the safety and feasibility of delivering enzyme replacement therapy ERT during pregnancy to fetuses diagnosed with Lysosomal Storage Diseases LSDs. These conditions carry a high risk of serious complications and death around birth, especially when associated with Non-Immune Hydrops Fetalis NIHF. The study aims to understand if starting ERT before birth can improve outcomes by reducing immune reactions and possibly supporting better brain development during critical periods. The study involves delivering ERT directly into the umbilical vein of the fetus in the womb. The dose depends on the specific LSD and the estimated fetal weight, matching the recommended postnatal weight-based dosing. This treatment is repeated every 2 to 4 weeks, a schedule chosen to balance safety and enzyme activity. This phase 1 trial focuses on determining if fetal enzyme therapy can be safely given and maintained throughout pregnancy. Participants will be pregnant women aged 18 to 50 carrying a fetus diagnosed with one of eight specific LSDs. Researchers will monitor for any treatment-related side effects, the ability to deliver full doses, enzyme activity in urine, and improvements in hydrops if present. Antibody levels against the enzyme will also be checked. The study involves multiple visits over pregnancy and will follow outcomes for up to six years to assess long-term safety and effectiveness.
CONDITIONS
PEARL (PrEnAtal Enzyme Replacement Therapy for Lysosomal Storage Disorders)
T
Tippi MacKenzie, MD
E
Emma Canepa, MS, CCRP
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of California, San Francisco
Lead Sponsor
Duke University
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | In utero ERT (PEARL trial) | Standard postnatal ERT (current practice) |
|---|---|---|
| What it is | Enzyme replacement given to the fetus before birth via infusion into the umbilical vein | Enzyme replacement therapy given after birth as standard treatment for lysosomal storage diseases |
| Role in trial | Investigational arm being evaluated for safety and feasibility in this phase 1 study | Not part of the trial arms |
| Primary use | To assess whether giving ERT before birth is safe and technically feasible for treating fetuses with severe lysosomal diseases | To treat infants with lysosomal storage diseases after birth in order to reduce disease progression |
| How it is given or performed | Weight‑based doses injected into the fetal umbilical vein using an in utero infusion procedure | Enzyme infusions administered after birth according to standard dosing schedules |
| Evidence status | Safety and feasibility being tested; limited case evidence including one Pompe disease fetus with favorable developmental follow‑up | Well‑established clinical benefit postnatally in reducing disease progression for many LSDs |
| Important risks | Fetal injection carries procedural risks to mother and fetus; unknown long‑term safety profile | Potential for immune responses and antibody development postnatally; risks vary by disease |
| Important limitations | Procedural complexity; still experimental with few human cases and limited safety data | Postnatal ERT may not prevent early organ damage or cross blood‑brain barrier effectively; immune response may limit benefit |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - From treatment initiation until birth
Participants receive enzyme replacement therapy administered in utero through the fetal umbilical vein. The therapy is given every 2 to 4 weeks during pregnancy to treat fetuses with lysosomal storage diseases.
Repeated visits every 2 to 4 weeks during pregnancy
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Yin-Hsiu Chien, Ni-Chung Lee, Beth L Thurberg...
https://pubmed.ncbi.nlm.nih.gov/19948615/Barry E Rosenbloom, Neal J Weinreb
https://pubmed.ncbi.nlm.nih.gov/23510062/A C M M Azevedo, I V Schwartz, L Kalakun...
https://pubmed.ncbi.nlm.nih.gov/15324318/Quoc-Hung Nguyen, Russell G Witt, Bowen Wang...
https://pubmed.ncbi.nlm.nih.gov/32102934/P J Meikle, J J Hopwood, A E Clague...
https://pubmed.ncbi.nlm.nih.gov/9918480/Suhrad G Banugaria, Sean N Prater, Yiu-Ki Ng...
https://pubmed.ncbi.nlm.nih.gov/21637107/Akos Herzeg, Beltran Borges, Billie R Lianoglou...
https://pubmed.ncbi.nlm.nih.gov/37955580/Beltran Borges, Emma Canepa, Irene J Chang...
https://pubmed.ncbi.nlm.nih.gov/39891377/Anne Chun-Hui Tsai, Yu-Wen Hung, Cary Harding...
https://pubmed.ncbi.nlm.nih.gov/28657663/Matthew J Blitz, Burton Rochelson, Monica Sood...
https://pubmed.ncbi.nlm.nih.gov/28374935/University of California, San Francisco
Lead Sponsor
Duke University
Collaborating Sponsor